Grifols Förvaltning
Förvaltning kriterier kontrolleras 2/4
Grifols VD är Nacho Abia Buenache, utsedd i Apr 2024, har en mandatperiod på 2.25 år. totala årliga ersättningen är € 3.52M, bestående av 56.9% lön 43.1% bonusar, inklusive företagsaktier och optioner. äger direkt 0.017% av företagets aktier, värda € 932.56K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 6 år respektive 4.1 år.
Viktig information
Nacho Abia Buenache
Verkställande direktör
€3.5m
Total ersättning
| VD-lön i procent | 56.87% |
| Anställning som VD | 2.3yrs |
| Ägande av VD | 0.02% |
| Ledningens genomsnittliga anställningstid | 6yrs |
| Styrelsens genomsnittliga mandatperiod | 4.1yrs |
Senaste uppdateringar av ledningen
Recent updates
GRF: New Bleeding Disorder Therapy And Margin Focus Will Drive Future Upside
Analysts have trimmed their price target on Grifols by €0.25, reflecting slightly lower fair value assumptions and updated views on discount rates, growth, and profitability, in line with recent Street research that reduced targets by about €1.00. Analyst Commentary Recent research on Grifols points to a more cautious stance on valuation, with price targets adjusted to reflect updated assumptions on growth, profitability, and discount rates.Grifols (BME:GRF) Stock Could Be 37.9% Undervalued After FESILTY Launch
Grifols (BME:GRF) has drawn fresh attention after launching FESILTY in the U.S., a fibrinogen concentrate for acute bleeding in patients with congenital fibrinogen deficiency, following recent FDA approval and supporting clinical data. See our latest analysis for Grifols. For investors, the FESILTY launch comes at a time when Grifols’ 1 day share price return of 1.04% and 7 day share price return of 0.75% sit against a year to date share price return that has declined 18.70%, while the 1 year...
GRF: Margin Protection And Biopharma Strength Will Support Future Upside
Analysts have reduced their price target on Grifols to €10 from €11, reflecting updated views on revenue growth and margins, as well as recent resets in Street forecasts following concerns around albumin and alpha-1 trends. Analyst Commentary Recent Street research reflects a more cautious stance on Grifols, with price targets reset to €10 and €11 and ratings aligned with a more neutral view.GRF: Margin Protection And US Biopharma IPO Plans Will Drive Future Upside
Analysts have trimmed their fair value estimate for Grifols from €15.08 to €14.65. This reflects recent cuts to Street price targets and concerns around slower albumin and alpha-1 volume growth that have led banks such as Deutsche Bank and Morgan Stanley to lower their expectations.GRF: Higher Required Returns Will Still Support Upside From Current Pricing
Analysts have trimmed their price targets on Grifols, with recent research such as the move from €15.00 to €13.50 supporting a modest reduction in our fair value estimate from €15.20 to about €15.08. They are factoring in slightly softer growth and margin assumptions alongside a higher expected discount rate, partly offset by a higher future P/E ratio.GRF: Execution On Profitability Reset And Higher P/E Will Unlock Upside
Analysts have nudged their fair value estimate for Grifols slightly lower to €21.72 from €21.78, reflecting reduced revenue growth and profit margin assumptions, alongside a higher future P/E, in line with recent Street moves such as Barclays trimming its price target to €13.50 from €15.00. Analyst Commentary Bullish analysts appear to be treating the latest target cut as more of a valuation reset than a shift in long term conviction, with the rating held at Overweight even as the price objective moves to €13.50 from €15.00.GRF: Higher Required Returns Will Still Support Attractive Future Earnings Multiple
Analysts have trimmed their valuation outlook for Grifols, reducing the implied price target from €15.20 to €15.03 as they factor in a higher discount rate and a slightly richer future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: Held broadly steady at €15.20, with only a marginal adjustment to the implied price target in the updated model.GRF: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have modestly reduced their price target on Grifols from approximately 23.00 dollars to 21.78 dollars, citing a higher perceived discount rate that more than offsets slightly stronger long term revenue growth and margin assumptions, along with a lower future price to earnings multiple. What's in the News Grifols has scheduled a Board meeting on September 25, 2025, to approve the creation of a Strategy Committee with an advisory role focused on strategic initiatives and developments, as defined in the Regulations of the Internal Functioning of the Board of Directors and the committee's own regulations (company filing).GRF: Upcoming Strategy Committee Will Support Improved Profit Margins Ahead
Analysts have slightly lowered their price target for Grifols from $15.45 to $15.20, citing minor adjustments to growth projections and profit expectations. What's in the News Grifols, S.A. is holding a Board Meeting on September 25, 2025, to establish a Strategy Committee with an advisory role focused on strategic initiatives and developments (Key Developments).GRF: Rising Margins and Board Initiatives Will Drive Future Performance
Analysts have lowered their price target for Grifols from $16.48 to $15.45, citing modestly reduced revenue growth expectations and a lower future price-to-earnings multiple. This comes despite slightly improved profit margins and a more favorable discount rate.
Biopharma Innovations And Tactical Strengths Propel Future Profitability And Market Expansion
Grifols' focus on innovation and new product development is poised to drive future revenue growth and market expansion.Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | €415m |
| Dec 31 2025 | €4m | €2m | €402m |
Ersättning vs marknad: Nacho s total kompensation ($USD 4.01M ) är över genomsnittet för företag av liknande storlek på Spanish marknaden ($USD 1.83M ).
Ersättning vs inkomst: Otillräcklig data för att jämföra Nacho s ersättning med företagets resultat.
VD OCH KONCERNCHEF
Nacho Abia Buenache (58 yo)
Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | €3.52m | 0.017% € 932.6k | |
| Chief Financial Officer | 1.8yrs | inga uppgifter | 0.011% € 610.4k | |
| Senior Vice President of Strategy & COO Office | no data | inga uppgifter | inga uppgifter | |
| Head of Investor Relations & Sustainability and Vice President | no data | inga uppgifter | inga uppgifter | |
| Chief Corporate Affairs & Legal Officer | 23.5yrs | inga uppgifter | 0.0029% € 158.4k | |
| Chief Compliance Officer | 7.5yrs | inga uppgifter | inga uppgifter | |
| Chief Communications and Reputation Officer | 1.3yrs | inga uppgifter | 0.0025% € 132.5k | |
| Chief Human Resources & Talent Officer | 2.4yrs | inga uppgifter | 0% € 0 | |
| Chief Quality Officer | 33.5yrs | inga uppgifter | 0% € 0 | |
| Chief Internal Audit & Enterprise Risk Manager | 4.5yrs | inga uppgifter | 0.0011% € 57.1k | |
| President of Commercial Tech Support | 7.5yrs | inga uppgifter | inga uppgifter | |
| Chief Industrial Services Officer | 7.5yrs | inga uppgifter | inga uppgifter |
Erfaren ledning: GRF s ledningsgrupp är erfaren och erfaren ( 6 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | €3.52m | 0.017% € 932.6k | |
| Proprietary Director | 1.6yrs | €129.00k | inga uppgifter | |
| Independent Director | 11.2yrs | €164.00k | inga uppgifter | |
| Chairman of Honour | no data | €129.00k | 0% € 0 | |
| Independent Director | 1.6yrs | €129.00k | inga uppgifter | |
| Member of the Advisory Committee | 11.5yrs | €380.00k | inga uppgifter | |
| Vice-Chairman | 11.2yrs | €129.00k | 0.0084% € 452.0k | |
| Independent External Director | 26.3yrs | €129.00k | 0.045% € 2.4m | |
| Proprietary Director | 10.2yrs | €4.45m | 0.023% € 1.2m | |
| Proprietary Director | 2.6yrs | €129.00k | 0.0097% € 522.6k | |
| Independent Director | 4.1yrs | €164.00k | inga uppgifter | |
| Independent Director | 4.1yrs | €154.00k | inga uppgifter |
Erfaren styrelse: GRF s styrelse anses vara erfaren ( 4.1 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/10 04:18 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Grifols, S.A. bevakas av 29 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |